Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

Regeneron is paying Hansoh Pharma $80 million upfront for a phase 3-stage GLP-1/GIP receptor – the deal could total up to $2 billion. Function Health is acquiring Ezra. ... Rx Rundown: BioNTech, Merck ...

Regeneron forms corporate VC unit with $100 million a year to invest over five years in biopharma, ... In early 2025, the White House renewed its push to lower prescription drug prices, ...

Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...

Twenty-seven states and the District of Columbia have filed a lawsuit in bankruptcy court seeking to block the sale of personal genetic data by 23andMe without customer consent.

The Trump administration is weighing measures that would make it more expensive for pharmaceutical companies to conduct ...

Senators Bernie Sanders and Angus King are preparing to introduce legislation that would ban pharmaceutical companies from advertising prescription drugs directly to consumers, The Wall Street Journal ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

The U.S. government is looking for ways to restrict the pharma sector’s direct-to-consumer advertising to make it more difficult and costly for companies to run advertisements directly targeting ...